Vivos net loss widens to $2.02 million in 1H FY26; revenue rises to $72,468 - RDGL News | RalliesVivos net loss widens to $2.02 million in 1H FY26; revenue rises to $72,468
R
RDGL• Business updates
- Business updates included FDA Early Feasibility IDE approval in July 2026 for a Mayo Clinic study, with 17 certified IsoPet clinics as of June 30.
Six-month results
- Vivos reported a net loss of $2.02 million for the six months ended June 30, 2026, widening from $1.48 million.
- Revenue rose to $72,468, up 73.58% year over year, driven by IsoPet therapies, IsoPet sales, and freight.
- Operating loss narrowed to $1.2 million from $1.54 million as operating expense fell to $1.19 million from $1.49 million.
- Non-operating results swung to a $815,013 loss from $58,096 income on a $847,628 loss on warrant exchanges.
•
